We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
-8.43%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$514M
AUM Growth
-$86.2M
(-14%)
Cap. Flow
-$11.8M
Cap. Flow
% of AUM
-2.3%
Top 10 Holdings %
Top 10 Hldgs %
22.06%
Holding
136
New
15
Increased
60
Reduced
35
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CONMED
CNMD
|
+$7.87M |
| 2 |
GoodRx Holdings
GDRX
|
+$6.71M |
| 3 |
Iovance Biotherapeutics
IOVA
|
+$6.43M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
+$5.7M |
| 5 |
Insulet
PODD
|
+$5.42M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Treace Medical Concepts
TMCI
|
+$9.71M |
| 2 |
Inspire Medical Systems
INSP
|
+$7.79M |
| 3 |
AGTI
Agiliti Inc
AGTI
|
+$7.74M |
| 4 |
Travere Therapeutics
TVTX
|
+$6.69M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
+$6.63M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.41% |
| 2 | Industrials | 2.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
BioMarin Pharmaceuticals
BMRN
$11.5B
| $12.8M | 2.5% |
145,090
-3,358
| -2% | -$299K |
|
2
Eli Lilly
LLY
$1.05T
| $12.5M | 2.43% |
23,265
-500
| -2% | -$258K |
|
3
Option Care Health
OPCH
$3.42B
| $12.1M | 2.37% |
375,500
-14,500
| -4% | -$489K |
|
|
4
CONMED
CNMD
$1.3B
| $11.5M | 2.24% |
114,000
+68,500
| +151% | +$7.87M |
|
5
Privia Health
PRVA
$3.35B
| $11.4M | 2.22% |
494,622
-12,000
| -2% | -$305K |
|
|
RCM
6
DELISTED
R1 RCM Inc. Common Stock
RCM
| $11.2M | 2.18% |
744,194
-65,000
| -8% | -$1.09M |
|
7
HealthEquity
HQY
$8.18B
| $10.5M | 2.05% |
143,875
-39,500
| -22% | -$2.67M |
|
8
Evolent Health
EVH
$643M
| $10.4M | 2.03% |
383,142
-105,000
| -22% | -$2.92M |
|
9
RadNet
RDNT
$4.76B
| $10.4M | 2.03% |
369,134
-29,500
| -7% | -$918K |
|
10
AtriCure
ATRC
$1.78B
| $10.4M | 2.02% |
236,532
-3,000
| -1% | -$146K |
|
|
FOLD
11
DELISTED
Amicus Therapeutics
FOLD
| $9.77M | 1.9% |
803,464
+73,540
| +10% | +$949K |
|
|
AXNX
12
DELISTED
Axonics, Inc. Common Stock
AXNX
| $9.71M | 1.89% |
172,950
+45,000
| +35% | +$2.53M |
|
|
NARI
13
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $9.03M | 1.76% |
138,043
-15,000
| -10% | -$944K |
|
14
Johnson & Johnson
JNJ
$603B
| $8.85M | 1.72% |
56,850
-5,250
| -8% | -$866K |
|
15
Insmed
INSM
$23.6B
| $8.77M | 1.71% |
347,392
-170,449
| -33% | -$3.9M |
|
16
UnitedHealth
UNH
$381B
| $8.53M | 1.66% |
16,925
-6,000
| -26% | -$2.95M |
|
|
BPMC
17
DELISTED
Blueprint Medicines
BPMC
| $8.33M | 1.62% |
165,890
+29,053
| +21% | +$1.55M |
|
18
Prothena Corp
PRTA
$452M
| $8.32M | 1.62% |
172,407
+20,559
| +14% | +$1.22M |
|
19
Icon
ICLR
$12.9B
| $8.29M | 1.61% |
33,663
-14,309
| -30% | -$3.61M |
|
20
Mineralys Therapeutics
MLYS
$2.35B
| $8M | 1.56% |
840,759
+226,046
| +37% | +$2.95M |
|
|
MRTX
21
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $7.92M | 1.54% |
181,904
+33,351
| +22% | +$1.19M |
|
22
Zentalis Pharmaceuticals
ZNTL
$371M
| $7.75M | 1.51% |
386,525
+152,525
| +65% | +$3.87M |
|
23
Amgen
AMGN
$198B
| $7.54M | 1.47% |
28,065
-204
| -0.7% | -$50.9K |
|
|
IMGN
24
DELISTED
Immunogen Inc
IMGN
| $7.37M | 1.43% |
464,112
+27,665
| +6% | +$460K |
|
25
Alkermes
ALKS
$8.74B
| $6.84M | 1.33% |
244,260
+2,087
| +0.9% | +$61.2K |
|
Similar funds
RIP
CCM
LFWA
FWA
CF
WIM
MW
AFC
Sectoral Asset Management's Q3 2023 Portfolio in Review
As of Q3 2023, Sectoral Asset Management held 136 positions worth $514M, down 14% from $600M the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Sectoral Asset Management's Q3 2023 filing shows 15 new, 60 increased, 35 reduced and 13 closed positions. Its largest new stake was GoodRx Holdings: 1,007,000 shares worth $5.67M. The largest sale was Treace Medical Concepts, an estimated $9.71M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Industrials.
- Sectoral Asset Management's largest Q3 2023 buy was GoodRx Holdings: 1,007,000 shares worth $5.67M.
- Sectoral Asset Management added most to CONMED in Q3 2023, an estimated $7.87M increase.
- Sectoral Asset Management's biggest Q3 2023 reduction was Amylyx Pharmaceuticals, cutting an estimated $6.63M.
- Sectoral Asset Management fully exited Treace Medical Concepts in Q3 2023, selling an estimated $9.71M.
- Sectoral Asset Management's ten largest holdings make up 22% of its $514M portfolio in Q3 2023.
- Sectoral Asset Management opened 15 new positions and closed 13 in Q3 2023.
- Sectoral Asset Management's portfolio value fell 14% quarter-over-quarter to $514M.
Based on Sectoral Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.